Subcutaneous Infection News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
News provided by
Share this article
Share this article
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathyroid hormone).
2. PaTHway China Trial is designed to assess the potential of TransCon™ PTH as a hormone replacement therapy, and the aim is to enable patients to have serum calcium (sCa) within the normal range and independence from usual care. ....

United States , Hong Kong , Jun Yang , Ascendis Pharma , Bone Mineral Research , Item Short Form Health Survey , National Medical Products Administration , Chinese Society Of Osteoporosis , Drug Evaluation , China Trial , Subcutaneous Infection , World Hypopara Awareness , Hypoparathyroidism Patient Experience Scale , Short Form Health Survey , World Hypopara Awareness Day , Greater China , Pharma Announces Orphan Drug Designation Granted , Hypoparathyroidism Retrieved Jun , Vivo Capital , Sofinnova Investments , Sequoia China , Sherpa Healthcare Partners , Venture Partners China , Logos Capital , Visen Pharma , ஒன்றுபட்டது மாநிலங்களில் ,